Merck (MRK) Tops Q3 EPS by 20c, Offers FY Guidance

Merck (NYSE: MRK) reported Q3 EPS of $1.75, $0.20 better than the analyst estimate of $1.55. Revenue for the quarter came in at $13.2 billion versus the consensus estimate of $12.33 billion.

GUIDANCE:

Merck sees FY2021 EPS of $5.65-$5.70, versus the consensus of $5.77. Merck sees FY2021 revenue of $47.4-47.9 billion, versus the consensus of $48.16 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Merck's tulisokibart meets Phase 3 endpoints in ulcerative colitis trial
• Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)